Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

PURPOSE: Although durable responses can be achieved with tyrosine kinase inhibitors such as imatinib in melanomas harboring KIT mutations, the efficacy of alternative inhibitors after progression to imatinib and the activity of these agents on brain metastases is unknown. EXPERIMENTAL DESIGN: We con...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Carvajal, Richard D., Lawrence, Donald P., Weber, Jeffrey S., Gajewski, Thomas F., Gonzalez, Rene, Lutzky, Jose, O’Day, Steven J., Hamid, Omid, Wolchok, Jedd D., Chapman, Paul B., Sullivan, Ryan J., Teitcher, Jerrold B., Ramaiya, Nikhil, Giobbie-Hurder, Anita, Antonescu, Cristina R., Heinrich, Michael C., Bastian, Boris C., Corless, Christopher L., Fletcher, Jonathan A., Hodi, F. Stephen
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5013827/
https://ncbi.nlm.nih.gov/pubmed/25695690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1630
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky